

11-14-05

IFW \$

Express Mail Label EV 326 989 055 US



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Tohyama, *et al.*

APPLICATION No.: 10/633,423

FILED: July 31, 2003

FOR: **COMPOSITION AND METHOD FOR NERVE
REGENERATION**

EXAMINER: Daniel E. Kolker

ART UNIT: 1614

CONF. NO: 3705

**Information Disclosure Statement After First Office Action but
Before Final Action or Notice of Allowance – 37 C.F.R. § 1.97(c)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

The information transmitted herewith is being filed *after* three months of the filing date of this application or after the mailing date of the first Office action on the merits, whichever occurred last, but *before* the mailing date of either a final action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. §1.311, whichever occurs first. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

- ☒ Copies of the following references can be found in parent U.S. Application No. 10/427,741.
- ☒ All cited references

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the

cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment (37 C.F.R. § 1.97(c)) or Certification (37 C.F.R. § 1.97(e))


- ☒ Applicant elects to pay the fee under 37 C.F.R. § 1.17(p) \$180.00.
- ☒ Check enclosed for \$180.00.
- ☒ Please charge any underpayment for timely filing of this paper to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 C.F.R. § 1.704(d))

- ☐ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Date: Nov. 10, 2005

Respectfully submitted,
Perkins Coie LLP



Jacqueline F. Mahoney
Registration No. 48,390

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)
(Use several sheets if necessary)

COMPLETE IF KNOWN

Application Number	10/633,423
Confirmation Number	3705
Filed	July 31, 2003
First Named Inventor	Masaya Tohyama
Group Art Unit	1614
Examiner Name	Daniel E. Kolker
Attorney Docket No.	59150-8023.US00

Sheet 1 of 6

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
		NUMBER	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	1	Buck, C.R. <i>et al.</i> , "Developmentally regulated expression of the nerve growth factor receptor gene in the periphery and brain," <i>Proc. Natl. Acad. Sci. USA</i> , 84 :3060-3063 (1987).	
	2	Davies, A.M., "Neurotrophins: Neurotrophic modulation of neurite growth," <i>Curr. Biol.</i> , 10 :R198-R200 (2000).	
	3	Ernfors, P. <i>et al.</i> , "Developmental and regional expression of beta-nerve growth factor receptor mRNA in the chick and rat", <i>Neuron.</i> , 1 :983-996 (1988).	
	4	Ernfors P. <i>et al.</i> , "Expression of nerve growth receptor mRNA is developmentally regulated and increased after axotomy in rat spinal cord motoneurons," <i>Neuron</i> , 2 :1605-1613 (1989).	
	5	Fainzilber, M. <i>et al.</i> , "CRNF, a molluscan neurotrophic factor that interacts with the p75 neurotrophin receptor," <i>Science.</i> , 274 :1540-1543 29 (1996).	
	6	Kimpinski, K. <i>et al.</i> , "The anti-P75 antibody, MC192, and brain-derived neurotrophic factor inhibit nerve growth factor-dependent neurite growth from adult sensory neurons," <i>Neuroscience</i> , 93 (1):253-263 (1999).	
	7	Kohn, J. <i>et al.</i> , "Functionally antagonistic interactions between the TrkA and p75 neurotrophin receptors regulate sympathetic neuron growth and target innervation," <i>J. Neuroscience</i> , 19 (13):5393-5408 (1999).	
	8	Large, T.H. <i>et al.</i> , "Structure and developmental expression of the nerve growth factor receptor in the chicken central nervous system," <i>Neuron</i> , 2 :1123-1134 (1989).	
	9	Lee, Kuo-Fen <i>et al.</i> , "Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system," <i>Cell</i> , 69 :737-749 (1992).	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)			COMPLETE IF KNOWN	
			Application Number	10/633,423
			Confirmation Number	3705
			Filed	July 31, 2003
			First Named Inventor	Masaya Tohyama
			Group Art Unit	1614
Examiner Name	Daniel E. Kolker			
Attorney Docket No.	59150-8023.US00			
Sheet 2 of 6				

10	Lehmann, M. <i>et al.</i> , "Inactivation of Rho signaling pathway promotes CNS axon regeneration," <i>J. Neuroscience</i> , 19 (17):7537-7547 (1999).
11	McKerracher, L. <i>et al.</i> , "Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth," <i>Neuron</i> , 13 :805-811 (1994).
12	Mukhopadhyay, G. <i>et al.</i> , "A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration," <i>Neuron</i> , 13 :757-767 (1994).
13	Ren, Xiang-Dong <i>et al.</i> , "Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton," <i>EMBO Journal</i> , 18 (3):578-585 (1999).
14	Roux, P. <i>et al.</i> , "p75 neurotrophin receptor expression is induced in apoptotic neurons after seizure", <i>J. Neuroscience</i> , 19 (16):6887-6896 (1999).
15	Sheikh, K. A. <i>et al.</i> , "Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects," <i>Proc. Natl. Acad. Sci. USA</i> , 96 :7532-7537 (1999).
16	Tang, S. <i>et al.</i> , "Myelin-associated glycoprotein interacts with neurons via a sialic acid binding site at ARG118 and a distinct neurite inhibition site," <i>J. Cell Biology</i> , 138 (6):1355-1366 (1997).
17	Tang, S. <i>et al.</i> , "Soluble myelin-associated glycoprotein (MAG) found <i>in vivo</i> inhibits axonal regeneration," <i>Molecular and Cellular Neuroscience</i> , 9 :333-346 (1997).
18	Tuffereau, C. <i>et al.</i> , "Low-affinity nerve-growth factor receptor (P75NTR) can serve as a receptor for rabies virus," <i>EMBO Journal</i> , 17 (24):7250-7259 (1998).
19	Vinson, M. <i>et al.</i> , "Myelin-associated glycoprotein interacts with ganglioside GT1b," <i>J. Biological Chemistry</i> , 276 (23):20280-20285 (2001).
20	Von Bartheld, C. <i>et al.</i> , "Expression of nerve growth factor (NGF) receptors in the brain and retina of chick embryos: comparison with cholinergic development," <i>J. Comparative Neurology</i> , 310 :103-129 (1991).
21	Walsh, G. <i>et al.</i> , "Enhanced neurotrophin-induced axon growth in myelinated portions of the CNS in mice lacking the p75 neurotrophin receptor," <i>J. Neuroscience</i> , 19 (10):4155-4168 (1999).
22	Yamashita, T. <i>et al.</i> , "Neurotrophin binding to the p75 receptor modulates Rho activity and axonal outgrowth," <i>Neuron</i> , 24 :585-593 (1999).
23	Yan, Q. and Johnson, E., "An immunohistochemical study of the nerve growth factor receptor in developing rats," <i>J. Neuroscience</i> , 8 (9):3481-3498 (1988).
24	Yang, L. <i>et al.</i> , "Gangliosides are neuronal ligands for myelin-associated glycoprotein," <i>Proc. Natl. Acad. Sci. USA</i> , 93 :814-818 (1996).
25	Yeo, T. <i>et al.</i> , "Absence of p75 ^{NTR} causes increased basal forebrain cholinergic neuron size, choline acetyltransferase activity, and target innervation," <i>J. Neuroscience</i> , 17 (20):7594-7605 (1997).
26	Amano, M. <i>et al.</i> , "Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase," <i>Science</i> , 275 :1308-1311 (1997).
27	Amano, M. <i>et al.</i> , "Myosin II activation promotes neurite retraction during the action of Rho and Rho-kinase," <i>Genes to Cells</i> , 3 :177-188 (1998).
28	Amano, M. <i>et al.</i> , "The COOH terminus of Rho-kinase negatively regulates Rho-kinase activity," <i>J. Biological Chemistry</i> , 274 (45):32418-32424 (1999).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)			COMPLETE IF KNOWN	
			Application Number	10/633,423
			Confirmation Number	3705
			Filed	July 31, 2003
			First Named Inventor	Masaya Tohyama
			Group Art Unit	1614
			Examiner Name	Daniel E. Kolker
Sheet 3 of 6			Attorney Docket No.	59150-8023.US00

29	Asada, M. <i>et al.</i> , "Apoptosis inhibitory activity of cytoplasmic p21 ^{Cip1/WAF1} in monocytic differentiation," <i>EMBO Journal</i> , 18 (5):1223-1234 (1999).
30	Cai, D. <i>et al.</i> , "Neuronal cyclic AMP controls the developmental loss in ability of axons to regenerate," <i>J. Neuroscience</i> , 21 (13):4731-4739 (2001).
31	Chen, J. <i>et al.</i> , "Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA," <i>Nature</i> , 374 :386-388 (1995).
32	DeBellard, M. <i>et al.</i> , "Myelin-associated glycoprotein inhibits axonal regeneration from a variety of neurons via interaction with a sialoglycoprotein," <i>Molecular and Cellular Neuroscience</i> , 7 :89-101 (1996).
33	Decker, Stuart J., "Nerve growth factor-induced growth arrest and induction of p21 ^{Cip1/WAF1} in NIH-3T3 cells expressing TrkA," <i>J. Biol. Chem.</i> , 270 (52):30841-30844 (1995).
34	Dobashi, Y. <i>et al.</i> , "Constitutive overexpression of CDK2 inhibits neuronal differentiation of rat pheochromocytoma PC12 cells," <i>J. Biol. Chem.</i> , 270 (39):23031-23037 (1995).
35	El-Diery, W. <i>et al.</i> , "WAF1, a potential mediator of p53 tumor suppression," <i>Cell</i> , 75 :817-825 (1993).
36	Erhardt, J. and Pittman, R., "Ectopic p21 ^{WAF1} expression induces differentiation-specific cell cycle changes in PC12 cells characteristic of nerve growth factor treatment," <i>J. Biol. Chem.</i> , 273 (36):23517-23523 (1998).
37	Frade, J. <i>et al.</i> , "Insulin-like growth factor-I stimulates neurogenesis in chick retina by regulating expression of the $\alpha 6$ integrin subunit," <i>Development</i> , 122 :2497-2506 (1996).
38	Frade, J. <i>et al.</i> , "Laminin-1 selectively stimulates neuron generation from cultured retinal neuroepithelial cells," <i>Experimental Cell Research</i> , 222 :140-149 (1996).
39	Frade, J. <i>et al.</i> , "Control of early cell death by BDNF in the chick retina," <i>Development</i> , 124 :3313-3320 (1997).
40	Gervais, J. <i>et al.</i> , "Cleavage of CDK inhibitor p21 ^{Cip1/Waf1} by caspases is an early event during DNA damage-induced apoptosis," <i>J. Biol. Chem.</i> , 273 (30):19207-19212 (1998).
41	Gollapudi, L. and Neet, K., "Different mechanisms for inhibition of cell proliferation via cell cycle proteins in PC12 cells by nerve growth factor and staurosporine," <i>J. Neuroscience Research</i> , 49 :461-474 (1997).
42	Goubin, F. and Ducommun, D., "Identification of binding domains on the p21 ^{Cip1} cyclin-dependent kinase inhibitor," <i>Oncogene</i> , 10 :2281-2287 (1995).
43	Harper, J. <i>et al.</i> , "The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases," <i>Cell</i> , 75 :805-816 (1993).
44	Hirose, M. <i>et al.</i> , "Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells," <i>J. Cell Biol.</i> , 141 (7):1625-1636, (1998).
45	Jiang, H. <i>et al.</i> , "Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53," <i>Oncogene</i> 9 :3397-3406 (1994).
46	Johnson, P. <i>et al.</i> , "Recombinant myelin-associated glycoprotein confers neural adhesion and neurite outgrowth function," <i>Neuron</i> , 3 :377-385 (1989).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)			COMPLETE IF KNOWN	
			Application Number	10/633,423
			Confirmation Number	3705
			Filed	July 31, 2003
			First Named Inventor	Masaya Tohyama
			Group Art Unit	1614
			Examiner Name	Daniel E. Kolker
Sheet 4 of 6			Attorney Docket No.	59150-8023.US00

47	Kimhi, Y. <i>et al.</i> , "Maturation of neuroblastoma cells in the presence of dimethylsulfoxide," <i>Proc. Natl. Acad. Sci. USA</i> , 73 (2):462-466 (1976).
48	Kranenburg, O. <i>et al.</i> , "Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells," <i>J. Cell Biol.</i> , 131 (1):227-234 (1995).
49	Kureishi, Y. <i>et al.</i> , "Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation," <i>J. Biol. Chem.</i> , 272 (19):12257-12260 (1997).
50	Lang, I. <i>et al.</i> , "Molecular mobility and nucleocytoplasmic flux in hepatoma cells," <i>J. Cell Biol.</i> , 102 :1183-1190 (1986).
51	Leung, T. <i>et al.</i> , "The p160 RhoA-binding kinase ROK α is a member of a kinase family and is involved in the reorganization of the cytoskeleton," <i>Molecular and Cellular Biology</i> , 16 (10):5313-5327 (1996).
52	Levkau, B. <i>et al.</i> , "Cleavage of p21 ^{Cip1/Waf1} and p27 ^{Kip1} mediates apoptosis in endothelial cells through activation of Cdk2: Role of a caspase cascade," <i>Molecular Cell</i> , 1 :553-563 (1998).
53	Lübbert, M. <i>et al.</i> , "Expression and regulation of myeloid-specific genes in normal and leukemic myeloid cells," <i>Blood</i> , 77 (5):909-924 (1991).
54	Luo, L., "Rho GTPases in neuronal morphogenesis," <i>Neuroscience</i> , 1 :173-180 (2000).
55	Luo, Y. <i>et al.</i> , "Cell-cycle inhibition by independent CDK and PCNA binding domains in p21 ^{Cip1} ," <i>Nature</i> , 375 :159-161 (1995).
56	Matsui, T. <i>et al.</i> , "Rho-associated kinase, a novel serine/threonine kinase, as a putative target for the small GTP binding protein Rho," <i>EMBO Journal</i> , 15 (9):2208-2216 (1996).
57	Neumann, H. <i>et al.</i> , "Tumor necrosis factor inhibits neurite outgrowth and branching of hippocampal neurons by a Rho-dependent mechanism," <i>J. Neuroscience</i> , 22 (3):854-862 (2002).
58	Noda, A. <i>et al.</i> , "Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen," <i>Experimental Cell Research</i> , 211 :90-98 (1994).
59	Pines, J., "Cyclins and cyclin-dependent kinases: a biochemical view," <i>J. Biochem.</i> , 308 :697-711 (1995).
60	Poluha, W. <i>et al.</i> , "The cyclin-dependent kinase inhibitor p21 ^{WAF1} is required for survival of differentiating neuroblastoma cells," <i>Molecular and Cellular Biology</i> , 16 (4):1335-1341 (1996).
61	Ridley, A. and Hall A., "The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors," <i>Cell</i> , 70 :389-399 (1992).
62	Rössig, L. <i>et al.</i> , "Akt-dependent phosphorylation of p21 ^{Cip1} regulates PCNA binding and proliferation of endothelial cells," <i>Molecular and Cellular Biology</i> , 21 (16):5644-5657 (2001).
63	Sebök, A. <i>et al.</i> , "Different roles for RhoA during neurite initiation, elongation, and regeneration in PC12 cells," <i>J. Neurochemistry</i> , 73 (3):949-960 (1999).
64	Sherr, C. and Roberts, J., "Inhibitors of mammalian G ₁ cyclin-dependent kinases," <i>Genes & Development</i> , 9 :1149-1163 (1995).
65	Uehata, M. <i>et al.</i> , "Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension," <i>Nature</i> , 389 :990-994 (1997).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)		COMPLETE IF KNOWN		
		Application Number	10/633,423	
		Confirmation Number	3705	
		Filed	July 31, 2003	
		First Named Inventor	Masaya Tohyama	
		Group Art Unit	1614	
		Examiner Name	Daniel E. Kolker	
Sheet 5 of 6			Attorney Docket No.	59150-8023.US00

66	Grunsvén, L. <i>et al.</i> , "Effect of nerve growth factor on the expression of cell cycle regulatory proteins in PC12 cells: dissection of the neurotrophic response from the anti-mitogenic response," <i>Oncogene</i> , 12 :1347-1356 (1996).
67	Waga, S. <i>et al.</i> , "The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA," <i>Nature</i> , 369 :574-578 (1994).
68	Watanabe, N. <i>et al.</i> , "Cooperation between mDia1 and ROCK in Rho-induced actin reorganization," <i>Nature Cell Biology</i> , 1 :136-143 (1999).
69	Yan, G. and Ziff, E., "NGF regulates the PC12 cell cycle machinery through specific inhibition of the Cdk kinases and induction of cyclin D1," <i>J. Neuroscience</i> , 15 (9):6200-6212 (1995).
70	Yasui, Y. <i>et al.</i> , "Roles of Rho-associated kinase in cytokinesis; mutations in Rho-associated kinase phosphorylation sites impair cytokinetic segregation of glial filaments," <i>J. Cell Biol.</i> , 143 (5):1249-1258 (1998).
71	Zhang, Y. <i>et al.</i> , "Caspase-mediated cleavage of p21 ^{Waf1/Cip1} converts cancer cells from growth arrest to undergoing apoptosis," <i>Oncogene</i> , 18 :1131-1138 (1999).
72	Zhou, B. <i>et al.</i> , "Cytoplasmic localization of p21 ^{Cip1/WAF1} by Akt-induced phosphorylation in HER-2/neu-overexpressing cells," <i>Nature Cell Biology</i> , 3 :245-252 (2001).
73	Dechant, G. and Barde, Y., "The neurotrophin receptor p75 ^{NTR} : novel functions and implications for diseases of the nervous system," <i>Nature Neuroscience</i> , 5 (11):1131-1136 (2002).
74	Schmidt, A. and Hall, A., "Guanine nucleotide exchange factors for Rho GTPases: turning on the switch," <i>Genes & Development</i> , 15 :1587-1609 (2002).
75	Wang, K. <i>et al.</i> , "p75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp," <i>Nature</i> , 420 :74-78 (2002).
76	Wong, S. <i>et al.</i> , "A p75 ^{NTR} and Nogo receptor complex mediates repulsive signaling by myelin-associated glycoprotein," <i>Nature Neuroscience</i> , 5 (12):1302-1308 (2002).
77	Sasaki, T. and Takai, Y., "The Rho small G protein family-Rho GDI system as a temporal and spatial determinant for cytoskeletal control," <i>Biochemical and Biophysical Research Communications</i> , 245 :641-645 (1998).
78	Fournier, A. <i>et al.</i> , "Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration," <i>Nature</i> , 409 :341-346 (2001).
79	Masuda, T. <i>et al.</i> , "Molecular cloning and characterization of yeast rho GDP dissociation inhibitor," <i>J. Biol. Chem.</i> , 269 (31):19713-19718 (1994).
80	Feinstein, D. and Larhammar, D., "Identification of a conserved protein motif in a group of growth factor receptors," <i>FEBS Lett.</i> , 272 (1)(2):7-11 (1990).
81	Koch, G. <i>et al.</i> , "Interaction of mastoparan with the low molecular mass GTP-binding proteins rho/rac," <i>FEBS Lett.</i> , 291 (2):336-340 (1991).
82	Takahashi, K. <i>et al.</i> , "Direct interaction of the Rho GDP dissociation inhibitor with Ezrin/Radixin/Moesin initiates the activation of the Rho small G protein," <i>J. Biol. Chem.</i> , 272 (37):23371-23375 (1997).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)			COMPLETE IF KNOWN	
			Application Number	10/633,423
			Confirmation Number	3705
			Filed	July 31, 2003
			First Named Inventor	Masaya Tohyama
			Group Art Unit	1614
Sheet 6 of 6			Examiner Name	Daniel E. Kolker
			Attorney Docket No.	59150-8023.US00

83	Yaku, H. <i>et al.</i> , "The Dbl Oncogene product as a GDP/GTP exchange protein for the Rho family: its properties in comparison with those of <i>SmgGDS</i> ¹ , <i>Biochemical and Biophysical Research Communications</i> , 198 (2):811-817 (1994).
84	llag, L. <i>et al.</i> , "Selection of a peptide ligand to the p75 neurotrophin receptor death domain and determination of its binding sites by NMR," <i>Biochemical and Biophysical Research Communications</i> , 255 :104-109 (1999).
85	Schwarze, S. <i>et al.</i> , "In vivo protein transduction: delivery of a biologically active protein into the mouse," <i>Science</i> , 285 :1569-1572 (1999).
86	Bentley, C. and Lee, K., "p75 is important for axon growth and Schwann cell migration during development," <i>J. Neuroscience</i> , 20 (20):7706-7715 (2000).
87	Walsh, G. <i>et al.</i> , "Enhanced neurotrophin-induced axon growth in myelinated portions of the CNS in mice lacking the p75 neurotrophin receptor," <i>J. Neuroscience</i> , 19 (10):4155-4168 (1999).
88	Lee, K. <i>et al.</i> , "Dependence on p75 for innervation of some sympathetic targets," <i>Science</i> , 263 :1447-1449 (1994).
89	McQuillen, P. <i>et al.</i> , "A novel role for p75NTR in subplate growth cone complexity and visual thalamocortical innervation," <i>J. Neuroscience</i> , 22 (9):3580-3593 (2002).
90	Del Pozo, M. <i>et al.</i> , "Integrins regulate GTP-Rac localized effector interactions through dissociation of Rho-GDI," <i>Nature Cell Biology</i> , 4 :232-239 (2002).
91	von Schack, D. <i>et al.</i> , "Complete ablation of the neurotrophin receptor p75 ^{NTR} causes defects both in the nervous and the vascular system," <i>Nature Neuroscience</i> , 4 (10):977-978 (2001).
92	Yamashita, T. <i>et al.</i> , "The p75 receptor transduces the signal from myelin-associated glycoprotein to Rho," <i>J. Cell Biology</i> , 157 (4):565-570 (2002).
93	Tanaka, H. <i>et al.</i> , "Cytoplasmic p21 ^{Cip1/WAF1} regulates neurite remodeling by inhibiting Rho-kinase activity," <i>J. Cell Biology</i> , 158 (2):321-329 (2002).
94	In This Issue, <i>J. Cell Biology</i> , 157 (4):544 (2002).
95	In This Issue, <i>J. Cell Biology</i> , 158 (2):192 (2002).
96	Morgan, K., "Unnerved: Molecule that pumps neurons up also keep them down (Neurodegeneration)," <i>Science Now</i> (2002).
97	Davenport, R., "The Nerve of Youth", <i>Science Now</i> (2002).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	